Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML)
Launched by ABBVIE · Mar 31, 2021
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the safety and effectiveness of a medication called oral venetoclax in adults with Acute Myeloid Leukemia (AML), a serious type of cancer affecting white blood cells. The trial is open to individuals aged 19 and older who have just been prescribed venetoclax for the first time as part of their treatment. Researchers will monitor how well the drug works and any side effects participants may experience over a period of seven months, with regular visits to their healthcare provider for check-ups and tests.
Participants in the study will take the venetoclax tablets as advised by their doctors and will be closely observed throughout the treatment. While this trial may involve more frequent hospital visits and assessments than standard care, it aims to gather important information about the drug’s effects on AML. It’s important to note that individuals who cannot take venetoclax for specific medical reasons or who are already participating in other clinical trials will not be eligible for this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • --Acute Myeloid Leukemia (AML) participants who have been prescribed oral Venetoclax tablets for the first time according to the approved label.
- Exclusion Criteria:
- • Participants with contraindications to Venetoclax as listed on the approved local label.
- • Participants receiving Venetoclax in clinical trials.
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Seoul, Seoul Teugbyeolsi, Korea, Republic Of
Busan, , Korea, Republic Of
Daegu, , Korea, Republic Of
Incheon, , Korea, Republic Of
Seoul, , Korea, Republic Of
Busan, , Korea, Republic Of
Busan, Busan Gwang Yeogsi, Korea, Republic Of
중구, Daegu Gwang Yeogsi, Korea, Republic Of
Incheon, Gyeonggido, Korea, Republic Of
Hwasun Gun, Jeonranamdo, Korea, Republic Of
Seoul, , Korea, Republic Of
Busan, Busan Gwang Yeogsi, Korea, Republic Of
Daegu, Daegu Gwang Yeogsi, Korea, Republic Of
Seoul, Seoul Teugbyeolsi, Korea, Republic Of
Seoul, Seoul Teugbyeolsi, Korea, Republic Of
Seoul, Seoul Teugbyeolsi, Korea, Republic Of
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
ABBVIE INC.
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials